Among 193 (80.8%) patients with DLBCL who received 1st-line treatment with R-CHOP-like (R-CHOP, R-CVOP where V is for etoposide, and R-CEOP where E is for epirubicin)/CHOP or R-COP/COP (Fig. 1), 81.3% achieved a CR/PR (Fig. 2, Table S5). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.